The efficacy of t acrolimus on the treatment of Takayasu arteritis

Hu Chen; Zhe Chen; Jing LI; Yunjiao Yang; Jiuliang Zhao; Min Liu; Xinping Tian

Return

The efficacy of t acrolimus on the treatment of Takayasu arteritis

VernacularTitle:他克莫司在中国多发性大动脉炎患者中的疗效分析
Author: Hu CHEN ; Zhe CHEN ; Jing LI ; Yunjiao YANG ; Jiuliang ZHAO ; Min LIU ; Xinping TIAN
Keywords: Takayasu's arteritis; Tacrolimus; Treatment outcome
From:Chinese Journal of Rheumatology 2017;21(8):536-541
CountryChina
Language:Chinese
Abstract: Objective To explore the efficacy and safety of tacrolimus among Chinese Takayasu arteritis (TAK) patients. Methods This was a single center, prospective study of active TAK patients treated with tacrolimus. Clinical manifestations, white blood cell count, hemoglobin level, erythrocyte sedimentation rate (ESR), hypersensitivity C reactive protein (hsCRP), alanine and aspartate aminotransferase and serum creatinine were recorded before and during tacrolimus treatment. Vascular changes were repeated every 6 months during tacrolimus treatment. All data were analyzed by statistical product and service solutions (SPSS) 20.0 statistical software, unpaired t test and Fisher exact probability and Kruskal-Wallis H test were used for statistical analysis. Results A total of 19 consecutive patients with an average age of (26 ±6) years were analyzed in this study. Sixteen of them were women. Pulselessness, fatigue, asymmetric blood pressure and fever were the most common clinical findings. Cervical and subclavian artery were more vulnerable. The most common artery involvement pattern was Numano type Ⅰ, followed by type Ⅱa and type Ⅴ. The median tacrolimus dosage was 2(2, 3) mg. Tacrolimus was effective in 9 out of the 19 patients. Patients who responded to tacrolimus tended to have lower mean ESR [(33±29) mm/1 h vs (42±20) mm/1 h, t=-0.776, P=0.448] and hsCRP [(20 ±31) mg/L vs (54 ±45) mg/L, t=-1.758, P=0.099] levels. However, no statistical significance was observed. During tacrolimus treatment, no drug related side effect was observed. Conclusion Tacrolimus is an alternative and effective therapy for some of the TAK patients.